Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2209–2232 of 6,602 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Autistic Disorder
Interventions: Placebo, RO5028442; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Los Ageles, California • New Haven, Connecticut • The Bronx, New York

Conditions: Carcinoma, Hepatocellular
Interventions: Mapatumumab, Placebo, Sorafenib; Drug
Lead sponsor: Human Genome Sciences Inc., a GSK Company; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 9
States / cities: Aurora, Colorado • Shreveport, Louisiana • Rochester, Minnesota + 5 more

Conditions: Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD
Interventions: PBGENE-DMD (IV); Biological
Lead sponsor: Precision BioSciences, Inc.; Industry
Eligibility: 2 Years to 7 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Little Rock, Arkansas • St Louis, Missouri

Conditions: Papillary Renal Cell Carcinoma
Interventions: savolitinib, durvalumab, sunitinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Diabetes Mellitus Type 2
Interventions: GK Activator (2), Metformin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 22
States / cities: Chula Vista, California • Los Angeles, California • Spring Valley, California + 18 more

Conditions: Multiple Sclerosis, Spinal Cord Injury
Interventions: Motivational interviewing, Education; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 45 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Myopia
Interventions: galyfilcon A, BC 8.30, lotrafilcon B, BC 8.60, comfilcon A, BC 8.60; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 18 Years to 39 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 35
States / cities: Brea, California • Campbell, California • Cupertino, California + 31 more

Conditions: Intensive Care Unit Acquired Weakness, Critical Care, Mechanical Ventilation, Respiratory Failure
Interventions: In-Bed Cycle Ergometer, Routine PT; Device · Other
Lead sponsor: McMaster University; Other
Eligibility: 18 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Baltimore, Maryland • Durham, North Carolina

Conditions: Drug Interactions
Interventions: Fexofenadine, Telotristat etiprate; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Sarcoma
Interventions: Gemcitabine and Pazopanib, Gemcitabine and Docetaxel; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 8
States / cities: Tucson, Arizona • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Diabetic Neuropathies
Interventions: SSR180575, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Total Knee Arthroplasty
Interventions: Total Knee Arthroplasty; Device
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 18 Years to 85 Years
Enrollment: 201 participants
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Multiple Sclerosis, Lower Urinary Tract Symptoms, Neurogenic Bladder, Detrusor, Overactive, Urge Incontinence
Interventions: Intra-detrusor injection of Onabotulinumtoxin-A; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Meningitis, Meningococcal
Interventions: Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 2 Months to 2 Months
Enrollment: 4,545 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 53
States / cities: Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 383 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Parkinson Disease, Multiple System Atrophy, Parkinson Variant, Progressive Supranuclear Palsy
Interventions: AIDP; Diagnostic Test
Lead sponsor: University of Florida; Other
Eligibility: 40 Years to 80 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 19
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 15 more

Conditions: Plasma Cell Myeloma
Interventions: Cessation of continuous matinenace therapy; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Rheumatoid Arthritis
Interventions: fostamatinib, placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 30
States / cities: Huntsville, Alabama • Huntington Beach, California • Santa Maria, California + 27 more

Conditions: Post Traumatic Stress Disorder
Interventions: Intervention D SLS-002, Intervention D Placebo; Drug
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2028 – 2029
U.S. locations: 9
States / cities: Miami, Florida • Atlanta, Georgia • Tripler AMC, Hawaii + 6 more

Conditions: Wrinkle
Interventions: MCD; Device
Lead sponsor: Cytrellis Biosystems, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 6
States / cities: Sacramento, California • Greenwood Village, Colorado • Miami, Florida + 3 more

Conditions: Carcinoma, Hepatocellular
Interventions: Everolimus, Tacrolimus, Myfortic, CellCept, Imuran; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 9
States / cities: San Francisco, California • Chicago, Illinois • Kansas City, Kansas + 6 more

Conditions: Advanced Solid Tumors, Selected Solid Tumors
Interventions: BKM120 + MEK162; Drug
Lead sponsor: Array Biopharma, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 5
States / cities: Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more

Conditions: Cystic Fibrosis
Interventions: MP-376 (Levofloxacin solution for Inhalation); Drug
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 6
States / cities: Mobile, Alabama • San Diego, California • Orlando, Florida + 3 more

Conditions: Age-Related Macular Degeneration
Interventions: 2.0 mg DE-122 Injectable Solution + Lucentis, 4.0 mg DE-122 Injectable Solution + Lucentis, Lucentis; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 10
States / cities: Gilbert, Arizona • Beverly Hills, California • Mountain View, California + 7 more

Search by objective public record fields.

A Study of RO5028442 in Adult Male High-Functioning Autistic Patients

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.

Motivational Interviewing to Increase Physical Activity to Treat Depression in People Aging With MS or SCI

Multi-Center 2-Week Clinical Evaluation of Three Silicone Hydrogel Contact Lenses

CYCLE: A Randomized Clinical Trial of Early In-bed Cycling for Mechanically Ventilated Patients

An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects

A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

Dose-effect of SSR180575 in Diabetic Neuropathy

Journey 2 Multi Center Kinematic Study

Central Nervous System Changes Following OnabotulinumtoxinA Injection in the Bladder

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological Surveillance

Automated Imaging Differentiation of Parkinsonism

Stopping Maintenance Therapy in People With Multiple Myeloma in MRD-Negative Remission

Study of the Effect of Fostamatinib Twice Daily on Blood Pressure in Patients With Rheumatoid Arthritis

Department of Defense PTSD Adaptive Platform Trial - Intervention D - SLS-002

Study to Evaluate the Safety and Efficacy of the Cytrellis Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles

Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients

"Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects